1 active not recruiting, 1 recruiting. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Vyxeos: new trials by email Literature Review of Vyxeos trials Research Report on Vyxeos
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection - Acute Myeloid Leukemia | Phase 3 | Recruiting | Children's Oncology Group | 1400 | 2020-07-21 | 2026-09-17 |
| A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT Vyxeos, Fludarabine, Busulphan - Acute Myeloid Leukaemia, High-risk Myelodysplastic Syndrome | Phase 2 / Phase 3 | Active not recruiting | University of Birmingham | 333 | 2020-01-27 | 2026-05-05 |
Children's Oncology Group (1) · University of Birmingham (1)
Australia (1) · Canada (1) · Puerto Rico (1) · United Kingdom (1) · United States (1)
Charles Craddock, Professor (1) · Todd M Cooper (1)
PMID 33843815, PMID 38107263, PMID 38947228, PMID 42497367
U10CA180886 (1)